Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 906082, 15 pages
http://dx.doi.org/10.1155/2010/906082
Review Article

Challenges for Biomarker Discovery in Body Fluids Using SELDI-TOF-MS

1Laboratory of Clinical Chemistry, GIGA Research, University of Liège, CHU, B36, 4000 Liège 1, Belgium
2Department of Rheumatology, GIGA Research, University of Liège, CHU, B36, 4000 Liège 1, Belgium
3Proteomic Platform, GIGA Research, University of Liège, CHU, B36, 4000 Liège 1, Belgium
4Department of Hepato-Gastroenterology, GIGA Research, University of Liège, CHU, B36, 4000 Liège 1, Belgium

Received 27 June 2009; Accepted 1 September 2009

Academic Editor: Pieter C. Dorrestein

Copyright © 2010 Muriel De Bock et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Liotta, M. Ferrari, and E. Petricoin, “Clinical proteomics: written in blood,” Nature, vol. 425, no. 6961, p. 905, 2003. View at Google Scholar · View at Scopus
  2. A. D. Westont and L. Hood, “Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine,” Journal of Proteome Research, vol. 3, no. 2, pp. 179–196, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Gorg, W. Weiss, and M. J. Dunn, “Current two-dimensional electrophoresis technology for proteomics,” Proteomics, vol. 4, no. 12, pp. 3665–3685, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Mitulovic, C. Stingl, M. Smoluch et al., “Automated, on-line two-dimensional nano liquid chromatography tandem mass spectrometry for rapid analysis of complex protein digests,” Proteomics, vol. 4, no. 9, pp. 2545–2557, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. R. S. Tirumalai, K. C. Chan, D. A. Prieto, H. J. Issaq, T. P. Conrads, and T. D. Veenstra, “Characterization of the low molecular weight human serum proteome,” Molecular & Cellular Proteomics, vol. 2, no. 10, pp. 1096–1103, 2003. View at Google Scholar · View at Scopus
  6. G. L. Wright Jr., “SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis,” Expert Review of Molecular Diagnostics, vol. 2, no. 6, pp. 549–563, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Hutchens and T. Yip, “New desorption strategies for the mass spectrometric analysis of macromolecules,” Rapid Commun Mass Spectrom, vol. 7, pp. 576–580, 1993. View at Google Scholar
  8. G. L. Wright Jr., L. H. Cazares, S.-M. Leung et al., “ProteinChip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures,” Prostate Cancer and Prostatic Diseases, vol. 2, no. 5-6, pp. 264–276, 1999. View at Google Scholar · View at Scopus
  9. N. Tang, P. Tornatore, and S. R. Weinberger, “Current developments in SELDI affinity technology,” Mass Spectrometry Reviews, vol. 23, no. 1, pp. 34–44, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Abramovitz and B. Leyland-Jones, “A systems approach to clinical oncology: focus on breast cancer,” Proteome Science, vol. 4, p. 5, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Bertucci, D. Birnbaum, and A. Goncalves, “Proteomics of breast cancer: principles and potential clinical applications,” Molecular and Cellular Proteomics, vol. 5, no. 10, pp. 1772–1786, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Bertucci and A. Goncalves, “Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery,” Future Oncology, vol. 4, no. 2, pp. 271–287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. A. P. Bons, M. P. van Dieijen-Visser, and W. K. W. H. Wodzig, “Clinical proteomics in chronic inflammatory diseases: a review,” Proteomics Clinical Applications, vol. 1, no. 9, pp. 1123–1133, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. C. S. Buhimschi, V. Bhandari, B. D. Hamar et al., “Proteomic profiling of the amniotic fluid to detect inflammation, infection, and neonatal sepsis,” PLoS Medicine, vol. 4, no. 1, article e18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. I. A. Buhimschi, E. Zambrano, C. M. Pettker et al., “Using proteomic analysis of the human amniotic fluid to identify histologic chorioamnionitis,” Obstetrics and Gynecology, vol. 111, no. 2, part 1, pp. 403–412, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. I. A. Buhimschi, G. Zhao, V. A. Rosenberg, S. Abdel-Razeq, S. Thung, and C. S. Buhimschi, “Multidimensional proteomics analysis of amniotic fluid to provide insight into the mechanisms of idiopathic preterm birth,” PLoS ONE, vol. 3, no. 4, article e2049, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. C. H. Clarke, J. A. Buckley, and E. T. Fung, “SELDI-TOF-MS proteomics of breast cancer,” Clinical Chemistry and Laboratory Medicine, vol. 43, no. 12, pp. 1314–1320, 2005. View at Google Scholar · View at Scopus
  18. D. de Seny, M. Fillet, M.-A. Meuwis et al., “Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteinchip approach,” Arthritis and Rheumatism, vol. 52, no. 12, pp. 3801–3812, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. D. de Seny, M. Fillet, C. Ribbens et al., “Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis,” Clinical Chemistry, vol. 54, no. 6, pp. 1066–1075, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. He, J. Gornbein, D. Shen et al., “Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry,” International Journal of Oncology, vol. 30, no. 1, pp. 145–154, 2007. View at Google Scholar · View at Scopus
  21. M. Hellstrom, H. Lexander, B. Franzen, and L. Egevad, “Proteomics in prostate cancer research,” Analytical and Quantitative Cytology and Histology, vol. 29, no. 1, pp. 32–40, 2007. View at Google Scholar · View at Scopus
  22. A. Hodgetts, M. Levin, J. S. Kroll, and P. R. Langford, “Biomarker discovery in infectious diseases using SELDI,” Future Microbiology, vol. 2, no. 1, pp. 35–49, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. J. T.-J. Huang, L. Wang, S. Prabakaran et al., “Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues,” Molecular Psychiatry, vol. 13, no. 12, pp. 1118–1128, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Hundt, U. Haug, and H. Brenner, “Blood markers for early detection of colorectal cancer: a systematic review,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 10, pp. 1935–1953, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. K. K. Jain, “Recent advances in clinical oncoproteomics,” Journal of Buon, vol. 12, supplement 1, pp. S31–S38, 2007. View at Google Scholar · View at Scopus
  26. Y. Mao, J. Yu, J. Chen et al., “Diagnosis of renal allograft subclinical rejection by urine protein fingerprint analysis,” Transplant Immunology, vol. 18, no. 3, pp. 255–259, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Martinez-Pinna, J. L. Martin-Ventura, S. Mas, L. M. Blanco-Colio, J. Tunon, and J. Egido, “Proteomics in atherosclerosis,” Current Atherosclerosis Reports, vol. 10, no. 3, pp. 209–215, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M.-A. Meuwis, M. Fillet, P. Geurts et al., “Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling,” Biochemical Pharmacology, vol. 73, no. 9, pp. 1422–1433, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M.-A. Meuwis, M. Fillet, L. Lutteri et al., “Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study,” Clinical Biochemistry, vol. 41, no. 12, pp. 960–967, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. S. J. Pitteri and S. M. Hanash, “Proteomic approaches for cancer biomarker discovery in plasma,” Expert Review of Proteomics, vol. 4, no. 5, pp. 589–590, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. E. R. Sauter, S. Shan, J. E. Hewett, P. Speckman, and G. C. Du Bois, “Proteomic analysis of nipple aspirate fluid using SELDl-TOF-MS,” International Journal of Cancer, vol. 114, no. 5, pp. 791–796, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Shen, J. Kim, E. F. Strittmatter et al., “Characterization of the human blood plasma proteome,” Proteomics, vol. 5, no. 15, pp. 4034–4045, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. A. H. Simonsen, J. McGuire, V. N. Podust et al., “Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease,” Neurobiology of Aging, vol. 29, no. 7, pp. 961–968, 2008. View at Google Scholar
  34. N. Tomosugi, K. Kitagawa, N. Takahashi, S. Sugai, and I. Ishikawat, “Diagnostic potential of tear proteomic patterns in Sjogren's syndrome,” Journal of Proteome Research, vol. 4, no. 3, pp. 820–825, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Zetterberg, U. Rüetschi, E. Portelius et al., “Clinical proteomics in neurodegenerative disorders,” Acta Neurologica Scandinavica, vol. 118, no. 1, pp. 1–11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Y. M. N. Engwegen, N. Mehra, J. B. A. G. Haanen et al., “Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations,” Laboratory Investigation, vol. 87, no. 2, pp. 161–172, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. D. M. Good, V. Thongboonkerd, J. Novak et al., “Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future,” Journal of Proteome Research, vol. 6, no. 12, pp. 4549–4555, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Kiehntopf, R. Siegmund, and T. Deufel, “Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 11, pp. 1435–1449, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. D. McLerran, W. E. Grizzle, Z. Feng et al., “Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias,” Clinical Chemistry, vol. 54, no. 1, pp. 44–52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. D. McLerran, W. E. Grizzle, Z. Feng et al., “SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer,” Clinical Chemistry, vol. 54, no. 1, pp. 53–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Villar-Garea, M. Griese, and A. Imhof, “Biomarker discovery from body fluids using mass spectrometry,” Journal of Chromatography B, vol. 849, no. 1-2, pp. 105–114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Maurya, P. Meleady, P. Dowling, and M. Clynes, “Proteomic approaches for serum biomarker discovery in cancer,” Anticancer Research, vol. 27, no. 3A, pp. 1247–1255, 2007. View at Google Scholar · View at Scopus
  43. T. L. Nickolas, J. Barasch, and P. Devarajan, “Biomarkers in acute and chronic kidney disease,” Current Opinion in Nephrology and Hypertension, vol. 17, no. 2, pp. 127–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. L. C. Whelan, K. A. R. Power, D. T. McDowell, J. Kennedy, and W. M. Gallagher, “Applications of SELDI-MS technology in oncology,” Journal of Cellular and Molecular Medicine, vol. 12, no. 5, pp. 1535–1547, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Findeisen and M. Neumaier, “Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 6, pp. 666–684, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Apweiler, C. Aslanidis, T. Deufel et al., “Approaching clinical proteomics: current state and future fields of application in fluid proteomics,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 6, pp. 724–744, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Albrethsen, R. Bogebo, J. Olsen, H. Raskov, and S. Gammeltoft, “Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum,” Clinical Chemistry and Laboratory Medicine, vol. 44, no. 10, pp. 1243–1252, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. R. E. Banks, A. J. Stanley, D. A. Cairns et al., “Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry,” Clinical Chemistry, vol. 51, no. 9, pp. 1637–1649, 2005. View at Google Scholar
  49. S. Barelli, D. Crettaz, L. Thadikkaran, O. Rubin, and J.-D. Tissot, “Plasma/serum proteomics: pre-analytical issues,” Expert Review of Proteomics, vol. 4, no. 3, pp. 363–370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Dijkstra, R. J. Vonk, and R. C. Jansen, “SELDI-TOF mass spectra: a view on sources of variation,” Journal of Chromatography B, vol. 847, no. 1, pp. 12–23, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. G. L. Hortin, “Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice?” Clinical Chemistry, vol. 51, no. 1, pp. 3–5, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. J. N. Mcguire, J. Overgaard, and F. Pociot, “Mass spectrometry is only one piece of the puzzle in clinical proteomics,” Briefings in Functional Genomics and Proteomics, vol. 7, no. 1, pp. 74–83, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Mischak, R. Apweiler, R. E. Banks et al., “Clinical proteomics: a need to define the field and to begin to set adequate standards,” Proteomics Clinical Applications, vol. 1, no. 2, pp. 148–156, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Papale, M. C. Pedicillo, B. J. Thatcher et al., “Urine profiling by SELDI-TOF/MS: monitoring of the critical steps in sample collection, handling and analysis,” Journal of Chromatography B, vol. 856, no. 1-2, pp. 205–213, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. T. C. W. Poon, “Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices,” Expert Review of Proteomics, vol. 4, no. 1, pp. 51–65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. A. J. Rai, C. A. Gelfand, B. C. Haywood et al., “HUPO plasma proteome project specimen collection and handling: towards the standardization of parameters for plasma proteome samples,” Proteomics, vol. 5, no. 13, pp. 3262–3277, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. A. J. Rai, P. M. Stemmer, Z. Zhang et al., “Analysis of human proteome organization plasma proteome project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers,” Proteomics, vol. 5, no. 13, pp. 3467–3474, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. A. J. Rai and F. Vitzthum, “Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics,” Expert Review of Proteomics, vol. 3, no. 4, pp. 409–426, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Rollin, T. Whistler, and S. D. Vernon, “Laboratory methods to improve SELDI peak detection and quantitation,” Proteome Science, vol. 5, p. 9, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Schipper, A. Loof, J. de Groot, L. Harthoorn, E. Dransfield, and W. van Heerde, “SELDI-TOF-MS of saliva: methodology and pre-treatment effects,” Journal of Chromatography B, vol. 847, no. 1, pp. 45–53, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. J. F. Timms, E. Arslan-Low, A. Gentry-Maharaj et al., “Preanalytic influence of sample handling on SELDI-TOF serum protein profiles,” Clinical Chemistry, vol. 53, no. 4, pp. 645–656, 2007. View at Google Scholar
  62. C. N. White, Z. Zhang, and D. W. Chan, “Quality control for SELDI analysis,” Clinical Chemistry and Laboratory Medicine, vol. 43, no. 2, pp. 125–126, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. O. J. Semmes, Z. Feng, B.-L. Adam et al., “Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility,” Clinical Chemistry, vol. 51, no. 1, pp. 102–112, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. K. A. Baggerly, J. S. Morris, and K. R. Coombes, “Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments,” Bioinformatics, vol. 20, no. 5, pp. 777–785, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Hu, K. R. Coombes, J. S. Morris, and K. A. Baggerly, “The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales,” Briefings in Functional Genomics and Proteomics, vol. 3, no. 4, pp. 322–331, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Hu, K. R. Coombes, J. S. Morris, and K. A. Baggerly, “The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales,” Briefings in Functional Genomics and Proteomics, vol. 3, no. 4, pp. 322–331, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. S.-Y. Hsieh, R.-K. Chen, Y.-H. Pan, and H.-L. Lee, “Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling,” Proteomics, vol. 6, no. 10, pp. 3189–3198, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. C. E. L. Dammann, M. Meyer, O. Dammann, and N. von Neuhoff, “Protein detection in dried blood by surface-enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF MS),” Biology of the Neonate, vol. 89, no. 2, pp. 126–132, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. F. H. Grus, V. N. Podust, K. Bruns et al., “SELDI-TOF-MS ProteinChip array profiling of tears from patients with dry eye,” Investigative Ophthalmology and Visual Science, vol. 46, no. 3, pp. 863–876, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Hu, J. A. Loo, and D. T. Wong, “Human body fluid proteome analysis,” Proteomics, vol. 6, no. 23, pp. 6326–6353, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. J. L. Noble, R. S. Dua, G. R. Coulton, C. M. Isacke, and G. P. H. Gui, “A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer,” European Journal of Cancer, vol. 43, no. 16, pp. 2315–2320, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. E. O'Riordan, T. N. Orlova, V. N. Podust et al., “Characterization of urinary peptide biomarkers of acute rejection in renal allografts,” American Journal of Transplantation, vol. 7, no. 4, pp. 930–940, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Papale, M. C. Pedicillo, S. Di Paolo et al., “Saliva analysis by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF/MS): from sample collection to data analysis,” Clinical Chemistry and Laboratory Medicine, vol. 46, no. 1, pp. 89–99, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. R. Schipper, A. Loof, J. de Groot, L. Harthoorn, W. van Heerde, and E. Dransfield, “Salivary protein/peptide profiling with SELDI-TOF-MS,” Annals of the New York Academy of Sciences, vol. 1098, pp. 498–503, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. F. J. Schweigert, B. Gericke, W. Wolfram, U. Kaisers, and J. W. Dudenhausen, “Peptide and protein profiles in serum and follicular fluid of women undergoing IVF,” Human Reproduction, vol. 21, no. 11, pp. 2960–2968, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. K. S. Shores and D. R. Knapp, “Assessment approach for evaluating high abundance protein depletion methods for cerebrospinal fluid (CSF) proteomic analysis,” Journal of Proteome Research, vol. 6, no. 9, pp. 3739–3751, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Suzuki, G. F. Ross, K. Wiers et al., “Identification of a urinary proteomic signature for lupus nephritis in children,” Pediatric Nephrology, vol. 22, no. 12, pp. 2047–2057, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Goncalves, E. Charafe-Jauffret, F. Bertucci et al., “Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes,” Molecular and Cellular Proteomics, vol. 7, no. 8, pp. 1420–1433, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Jansen, K. M. Hebeda, M. Linkels et al., “Protein profiling of B-cell lymphomas using tissue biopsies: a potential tool for small samples in pathology,” Cellular Oncology, vol. 30, no. 1, pp. 27–38, 2008. View at Google Scholar · View at Scopus
  80. S. Schaub, J. Wilkins, T. Weiler, K. Sangster, D. Rush, and P. Nickerson, “Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry,” Kidney International, vol. 65, no. 1, pp. 323–332, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Tammen, I. Schulte, R. Hess et al., “Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display,” Proteomics, vol. 5, no. 13, pp. 3414–3422, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Z. Traum, M. P. Wells, M. Aivado, T. A. Libermann, M. F. Ramoni, and A. D. Schachter, “SELDI-TOF MS of quadruplicate urine and serum samples to evaluate changes related to storage conditions,” Proteomics, vol. 6, no. 5, pp. 1676–1680, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. J. Yi, C. Kim, and C. A. Gelfand, “Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma,” Journal of Proteome Research, vol. 6, no. 5, pp. 1768–1781, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. A. E. Pelzer, I. Feuerstein, C. Fuchsberger et al., “Influence of blood sampling on protein profiling and pattern analysis using matrix-assisted laser desorption/ionisation mass spectrometry,” BJU International, vol. 99, no. 3, pp. 658–662, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. J. L. Luque-Garcia and T. A. Neubert, “Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry,” Journal of Chromatography A, vol. 1153, no. 1-2, pp. 259–276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Battino, M. S. Ferreiro, I. Gallardo, H. N. Newman, and P. Bullon, “The antioxidant capacity of saliva,” Journal of Clinical Periodontology, vol. 29, no. 3, pp. 189–194, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Voorbij, “Pouten en risiko's in een klinisch-chemisch laboratorium,” Nederlands Tijdschrift voor Klinische Chemie, vol. 19, pp. 36–41, 1994. View at Google Scholar
  88. A. Gagnon, Q. Shi, and B. Ye, “Surface-enhanced laser desorption/ionization mass spectrometry for protein and peptide profiling of body fluids,” Methods in Molecular Biology, vol. 441, pp. 41–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. G. MacGregor, R. D. Gray, T. N. Hilliard et al., “Biomarkers for cystic fibrosis lung disease: application of SELDI-TOF mass spectrometry to BAL fluid,” Journal of Cystic Fibrosis, vol. 7, no. 5, pp. 352–358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. J. T.-J. Huang, L. Wang, S. Prabakaran et al., “Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues,” Molecular Psychiatry, vol. 13, no. 12, pp. 1118–1128, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. N. L. Anderson and N. G. Anderson, “The human plasma proteome: history, character, and diagnostic prospects,” Molecular & Cellular Proteomics, vol. 1, no. 11, pp. 845–867, 2002. View at Google Scholar · View at Scopus
  92. M. A. Gillette, D. R. Mani, and S. A. Carr, “Place of pattern in proteomic biomarker discovery,” Journal of Proteome Research, vol. 4, no. 4, pp. 1143–1154, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. M. K. D. R. Dayarathna, W. S. Hancock, and M. Hincapie, “A two step fractionation approach for plasma proteomics using immunodepletion of abundant proteins and multi-lectin affinity chromatography: application to the analysis of obesity, diabetes, and hypertension diseases,” Journal of Separation Science, vol. 31, no. 6-7, pp. 1156–1166, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. X. Jiang, M. Ye, and H. Zou, “Technologies and methods for sample pretreatment in efficient proteome and peptidome analysis,” Proteomics, vol. 8, no. 4, pp. 686–705, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. P. Matt, Z. Fu, Q. Fu, and J. E. Van Eyk, “Biomarker discovery: proteome fractionation and separation in biological samples,” Physiological Genomics, vol. 33, no. 1, pp. 12–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Pernemalm, L. M. Orre, J. Lengqvist et al., “Evaluation of three principally different intact protein prefractionation methods for plasma biomarker discovery,” Journal of Proteome Research, vol. 7, no. 7, pp. 2712–2722, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. P. G. Righetti, E. Boschetti, L. Lomas, and A. Citterio, “Protein equalizer technology : the quest for a “democratic proteome”,” Proteomics, vol. 6, no. 14, pp. 3980–3992, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. K. S. Shores, D. G. Udugamasooriya, T. Kodadek, and D. R. Knapp, “Use of peptide analogue diversity library beads for increased depth of proteomic analysis: application to cerebrospinal fluid,” Journal of Proteome Research, vol. 7, no. 5, pp. 1922–1931, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Sihlbom, I. Kanmert, H. V. Bahr, and P. Davidsson, “Evaluation of the combination of bead technology with SELDI-TOF-MS and 2-D DIGE for detection of plasma proteins,” Journal of Proteome Research, vol. 7, no. 9, pp. 4191–4198, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. S. W. Tam, J. Pirro, and D. Hinerfeld, “Depletion and fractionation technologies in plasma proteomic analysis,” Expert Review of Proteomics, vol. 1, no. 4, pp. 411–420, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. J. R. Whiteaker, H. Zhang, J. K. Eng et al., “Head-to-head comparison of serum fractionation techniques,” Journal of Proteome Research, vol. 6, no. 2, pp. 828–836, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. F. E. Ahmed, “Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry,” Journal of Separation Science, vol. 32, no. 5-6, pp. 771–798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. N. Zolotarjova, P. Mrozinski, H. Chen, and J. Martosella, “Combination of affinity depletion of abundant proteins and reversed-phase fractionation in proteomic analysis of human plasma/serum,” Journal of Chromatography A, vol. 1189, no. 1-2, pp. 332–338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Pernemalm, R. Lewensohn, and J. Lehtio, “Affinity prefractionation for MS-based plasma proteomics,” Proteomics, vol. 9, no. 6, pp. 1420–1427, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. P. G. Righetti and E. Boschetti, “Sherlock Holmes and the proteome—a detective story,” FEBS Journal, vol. 274, no. 4, pp. 897–905, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. L. A. Liotta and E. F. Petricoin, “Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold,” The Journal of Clinical Investigation, vol. 116, no. 1, pp. 26–30, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. P. G. Righetti and E. Boschetti, “The ProteoMiner and the FortyNiners: searching for gold nuggets in the proteomic arena,” Mass Spectrometry Reviews, vol. 27, no. 6, pp. 596–608, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Castagna, D. Cecconi, L. Sennels et al., “Exploring the hidden human urinary proteome via ligand library beads,” Journal of Proteome Research, vol. 4, no. 6, pp. 1917–1930, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. L. Guerrier, S. Claverol, F. Fortis et al., “Exploring the platelet proteome via combinatorial, hexapeptide ligand libraries,” Journal of Proteome Research, vol. 6, no. 11, pp. 4290–4303, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. L. Sennels, M. Salek, L. Lomas, E. Boschetti, P. G. Righetti, and J. Rappsilber, “Proteomic analysis of human blood serum using peptide library beads,” Journal of Proteome Research, vol. 6, no. 10, pp. 4055–4062, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. V. Thulasiraman, S. Lin, L. Gheorghiu et al., “Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands,” Electrophoresis, vol. 26, no. 18, pp. 3561–3571, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. J. Albrethsen, “Reproducibility in protein profiling by MALDI-TOF mass spectrometry,” Clinical Chemistry, vol. 53, no. 5, pp. 852–858, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. L. M. Preston, K. K. Murray, and D. H. Russell, “Reproducibility and quantitation of matrix-assisted laser desorption ionization mass spectrometry: effects of nitrocellulose on peptide ion yields,” Biological Mass Spectrometry, vol. 22, no. 9, pp. 544–550, 1993. View at Google Scholar · View at Scopus
  114. L. Ekblad, B. Baldetorp, M. Ferno, H. Olsson, and C. Bratt, “In-source decay causes artifacts in SELDI-TOF MS spectra,” Journal of Proteome Research, vol. 6, no. 4, pp. 1609–1614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  115. D. A. Cairns, D. Thompson, D. N. Perkins, A. J. Stanley, P. J. Selby, and R. E. Banks, “Proteomic profiling using mass spectrometry—does normalising by total ion current potentially mask some biological differences?” Proteomics, vol. 8, no. 1, pp. 21–27, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. W. Meuleman, J. Y. M. N. Engwegen, M.-C. W. Gast, J. H. Beijnen, M. J. T. Reinders, and L. F. A. Wessels, “Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (SELDI) time-of-flight (TOF) mass spectrometry data,” BMC Bioinformatics, vol. 9, article 88, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. W. Wegdam, P. D. Moerland, M. R. Buist et al., “Classification-based comparison of pre-processing methods for interpretation of mass spectrometry generated clinical datasets,” Proteome Science, vol. 7, p. 19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. N. Jeffries, “Algorithms for alignment of mass spectrometry proteomic data,” Bioinformatics, vol. 21, no. 14, pp. 3066–3073, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. C. S. Tan, A. Ploner, A. Quandt, J. Lehtio, and Y. Pawitan, “Finding regions of significance in SELDI measurements for identifying protein biomarkers,” Bioinformatics, vol. 22, no. 12, pp. 1515–1523, 2006. View at Publisher · View at Google Scholar · View at Scopus
  120. F. M. Smith, W. M. Gallagher, E. Fox et al., “Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy,” Annals of Surgery, vol. 245, no. 2, pp. 259–266, 2007. View at Google Scholar
  121. P. Geurts, M. Fillet, D. de Seny et al., “Proteomic mass spectra classification using decision tree based ensemble methods,” Bioinformatics, vol. 21, no. 14, pp. 3138–3145, 2005. View at Publisher · View at Google Scholar · View at Scopus
  122. S. Smit, H. C. J. Hoefsloot, and A. K. Smilde, “Statistical data processing in clinical proteomics,” Journal of Chromatography B, vol. 866, no. 1-2, pp. 77–88, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. E. T. Fung, T.-T. Yip, L. Lomas et al., “Classification of cancer types by measuring variants of host response proteins using SELDI serum assays,” International Journal of Cancer, vol. 115, no. 5, pp. 783–789, 2005. View at Publisher · View at Google Scholar · View at Scopus
  124. J. Peng, A. J. Stanley, D. Cairns, P. J. Selby, and R. E. Banks, “Using the protein chip interface with quadrupole time-of-flight mass spectrometry to directly identify peaks in SELDI profiles—initial evaluation using low molecular weight serum peaks,” Proteomics, vol. 9, no. 2, pp. 492–498, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. R. N. H. Pugh, I. M. Murray Lyon, J. L. Dawson, M. C. Pietroni, and R. Williams, “Transection of the oesophagus for bleeding oesophageal varices,” British Journal of Surgery, vol. 60, no. 8, pp. 646–649, 1973. View at Google Scholar · View at Scopus
  126. L. Brugler, A. Stankovic, L. Bernstein, F. Scott, and J. O'Sullivan-Maillet, “The role of visceral protein markers in protein calorie malnutrition,” Clinical Chemistry and Laboratory Medicine, vol. 40, no. 12, pp. 1360–1369, 2002. View at Publisher · View at Google Scholar · View at Scopus
  127. P. B. Sehgal, “Interleukin-6: molecular pathophysiology,” Journal of Investigative Dermatology, vol. 94, no. 6, supplement, pp. 2S–6S, 1990. View at Google Scholar · View at Scopus
  128. E. P. Diamandis, “Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?” Clinical Chemistry, vol. 49, no. 8, pp. 1272–1275, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. N. Escher, M. Kaatz, C. Melle et al., “Posttranslational modifications of transthyretin are serum markers in patients with mycosis fungoides,” Neoplasia, vol. 9, no. 3, pp. 254–259, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. M. Ueda, Y. Misumi, M. Mizuguchi et al., “SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy,” Clinical Chemistry, vol. 55, no. 6, pp. 1223–1227, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. L. Chen, S. Fatima, J. Peng, and X. Leng, “SELDI protein chip technology for the detection of serum biomarkers for liver disease,” Protein and Peptide Letters, vol. 16, no. 5, pp. 467–472, 2009. View at Publisher · View at Google Scholar · View at Scopus
  132. B. Matharoo-Ball, G. Ball, and R. Rees, “Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches—a prostate cancer perspective,” Vaccine, vol. 25, supplement 2, pp. B110–B121, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. A. Skytt, E. Thysell, P. Stattin et al., “SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer,” International Journal of Cancer, vol. 121, no. 3, pp. 615–620, 2007. View at Google Scholar
  134. G. Xu, C. Q. Xiang, Y. Lu et al., “Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma,” Cancer Letters, vol. 282, no. 2, pp. 205–213, 2009. View at Publisher · View at Google Scholar · View at Scopus
  135. B. J. McMorran, S. A. O. Patat, J. B. Carlin et al., “Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis patients,” Clinical Chemistry, vol. 53, no. 10, pp. 1782–1791, 2007. View at Publisher · View at Google Scholar · View at Scopus
  136. C. Rocken, R. Ketterlinus, and M. P. A. Ebert, “Application of proteome analysis to the assessment of prognosis and response prediction in clinical oncology,” Current Cancer Drug Targets, vol. 8, no. 2, pp. 141–145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  137. C. Trocme, H. Marotte, A. Baillet et al., “Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 8, pp. 1328–1333, 2009. View at Publisher · View at Google Scholar · View at Scopus